Generate QR code
Open Access
Subscription Access
Comparative analysis of the effect of lisinopril and valsartan on the results of dynamic nephroscintigraphy in chronic pyelonephritis with arterial hypertension
https://doi.org/10.36485/1561-6274-2026-30-1-90-93
EDN: EJHJBD
Abstract
Bacterial infections currently pose a threat to human health, and in some cases, life. Urinary tract infections are a significant threat among them. Chronic pyelonephritis (chrPN), as a common cause of chronic kidney disease (CKD), is of significant importance in this regard.
THE AIM: to study the clinical and functional effects of antihypertensive drugs in patients with symptomatic arterial hypertension (AH) in the early stages of CKD due to chrPN, using a comparative analysis using dynamic renal scintigraphy.
PATIENT AND METHODS. Our study included 100 patients with CPN and hypertension, CKD C1-C3a, in remission.
RESULTS. Target blood pressure was achieved with ACE inhibitors and ARBs for 2 months. Estimated glomerular filtration rate (eGFR) did not change significantly. Lisinopril therapy had no effect on Tmax and Tmax–T½ in both kidneys. Improvement in secretory and excretory function in both kidneys was observed with valsartan.
CONCLUSION. A positive effect of valsartan was observed, suggesting it as a more promising drug for renal protection in patients with chronic kidney disease and hypertension.
About the Authors
S. A. Oskolkov
Tyumen State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Prof. Sergey A. Oskolkov, MD, PhD, DMedSci, Department of Propaedeutics of Internal Diseases
625049, Tyumen, Magnitogorsk str., 8
+7 (3452) 52-30-83
S. A. Paketov
Tyumen State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Associate Professor, Sergey A. Paketov, MD, PhD, Department of Propaedeutics of Internal Diseases
625049, Tyumen, Magnitogorsk str., 8
+7 (3452) 52-30-83
V. A. Zhmurov
Tyumen State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Prof. Vladimir A. Zhmurov, MD, PhD, DMediSci, Department of Propaedeutics of Internal Diseases
625049, Tyumen, Magnitogorsk str., 8
+7 (3452) 52-30-83
D. V. Zhmurov
Tyumen State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Associate Professor, Denis V. Zhmurov, MD, PhD, Department of Propaedeutics of Internal Diseases
625049, Tyumen, Magnitogorsk str., 8
+7 (3452) 52-30-83
References
1. Godaly G, Svanborg C. Urinary tract infections revisited. Kidney Int 2007 Apr;71(8):721–723. doi: 10.1038/sj.ki.5002170
2. Valenza G. Extended-Spectrum-β-lactamase-producing Escherichia coli as intestinal colonizers in the German community. Antimicrobial Agents Chemotherapy 2014;58(2):1228–1230. doi: 10.1128/AAC.01993-13
3. Kolesnik NA. Kidneys and diabetes mellitus: from understanding the problem to timely and adequate therapy. Ukrainian Journal of Nephrology and Dialysis 2009;13–14:13–15
4. Montagna MT, Tontodonati M, Manzoli L, Polilli E. Chronic kidney disease and urinary tract infections: The role of pyelonephritis. International Journal of Nephrology and Renovascular Disease 2015;8:201–210
5. Nephrology. Clinical guidelines. Edited by E.M. Shilov, A.V. Smirnov, and N.L. Kozlovskaya. GEOTAR-Media, M., 2020:856
6. Drapkina OM, Kobalava ZhD, Shestakova MV et al. Cardiovascular risk and chronic kidney disease: strategies for cardiac and renal protection. Interdisciplinary consensus. Cardiovascular Therapy and Prevention 2025;24(6):4466. (In Russ.) https://doi.org/10.15829/1728-8800-2025-4466. EDN: MIARUF
7. Kuzmin OB, Pugaeva MO, Buchneva NV. Renal mechanisms of nephrogenic arterial hypertension. Nephrology (Saint-Petersburg) 2008;12(2):39–46. (In Russ.) https://doi.org/10.24884/1561-6274-2008-12-2-39-46
8. Lishmanov YuB, Chernov VI. Radionuclide diagnostics for practitioners.STT, Tomsk, 2004, 394 p
9. Kuzmin OB, Zhezha VV, Belyanin VV, Landar LN. Drug therapy in patients with chronic kidney disease: is there a place for a dual inhibitor of neplysin and AT1-angiotensin receptors LCZ696 (sacubitril/valsartan)? Nephrology 2018;22(2):59–67
10. Kalaitzidis RG, Elisaf MS. Treatment of Hypertension in Chronic Kidney Disease. Current Hypertension Reports 2018; 20(8):64. doi: 10.1007/s11906-018-0864-0
Review
For citations:
Oskolkov S.A., Paketov S.A., Zhmurov V.A., Zhmurov D.V. Comparative analysis of the effect of lisinopril and valsartan on the results of dynamic nephroscintigraphy in chronic pyelonephritis with arterial hypertension. Nephrology (Saint-Petersburg). 2026;30(1):90-93. (In Russ.) https://doi.org/10.36485/1561-6274-2026-30-1-90-93. EDN: EJHJBD
Views:
187
JATS XML
Email this article 